Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of DE-117 in Healthy Males
NCT02650063Phase 1Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of omidenepag isopropyl in Glaucoma and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoints: Area under concentration-time curve at 7 days, Maximum plasma concentration at 7 days and 2 more. Started Dec 2015; status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT02650063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650063.